No Data
Tellgen Corporation (300642.SZ): Application for the change registration of medical instruments has been accepted.
On January 17, Gelonghui reported that Tellgen Corporation (300642.SZ) announced that the company recently received the "Acceptance Notification" issued by the National Medical Products Administration, accepting the company's application for a registration change of the "Human SHOX2 and RASSF1A gene methylation DNA detection kit (PCR fluorescence method)". The sample type for the company's Human SHOX2 and RASSF1A gene methylation DNA detection kit (PCR fluorescence method) is solely alveolar lavage fluid. Based on market and clinical usage needs, the company intends to apply to the National Medical Products Administration to expand the 'Human
Weak Statutory Earnings May Not Tell The Whole Story For Tellgen (SZSE:300642)
Perspective Life: Report for the third quarter of 2024
Tellgen Corporation (300642.SZ) released its performance for the first half of the year, with a net income of 24.3929 million yuan, a year-on-year decrease of 43.16%.
Tellgen Corporation (300642.SZ) released the third quarter report for 2024, with revenue of 3....
tellgen corporation (300642.SZ): net income in the third quarter was 17.7589 million yuan, a year-on-year increase of 120.53%.
On October 24, Guilonghui announced that in the third quarter of 2024, Tellgen Corporation (300642.SZ) achieved revenue of 0.105 billion yuan, a 15.92% year-on-year decrease; net income attributable to shareholders of the listed company was 17.7589 million yuan, an increase of 120.53% year-on-year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 11.2616 million yuan, an increase of 491.28% year-on-year; and basic earnings per share was 0.1094 yuan.
Calculating The Intrinsic Value Of Tellgen Corporation (SZSE:300642)
Need To Know: Analysts Just Made A Substantial Cut To Their Tellgen Corporation (SZSE:300642) Estimates
